MesoblastASX:MSB +0.49%46 3-Year ROIIC % is 14.06 as of Jun. 2025, which is 101% above its 10-year median of 7.01. GuruFocus rates ASX:MSB with a GF Score™ of 46/100. The stock has 4 warning signs investors should review. Among 1,324 Biotechnology companies, Mesoblast ranks better than 62.69% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Mesoblast's 3-Year ROIIC % for the quarter that ended in Jun. 2025 was 14.06%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Mesoblast's 3-Year ROIIC % or its related term are showing as below:
ASX:MSB's 3-Year ROIIC % is ranked better than 62.69% of 1324
companies
in the Biotechnology industry
Industry Median: -4.42
vs ASX:MSB: 14.06
Mesoblast (ASX:MSB) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Mesoblast 3-Year ROIIC % Related Terms
Mesoblast 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Mesoblast's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:MSB vs VRTX, REGN, ALNY: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, Mesoblast's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mesoblast 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Mesoblast's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Mesoblast's 3-Year ROIIC % falls into.
Mesoblast's 3-Year ROIIC % for the quarter that ended in Jun. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -95.912 (Jun. 2025) - -115.114921 (Jun. 2022) )
/
( 1019.715 (Jun. 2025) - 883.113 (Jun. 2022) )
=
19.202921
/
136.602
=
14.06%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Mesoblast (ASX:MSB) has a 3-Year ROIIC % of 14.06 as of Jun. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Mesoblast and its competitors. This is 101% above median its historical median of 7.01. According to the industry distribution chart, Mesoblast ranks #494 out of 1324 companies in the Biotechnology industry, placing it in the top 37.3%.
Is Mesoblast's 3-Year ROIIC % too high?
Mesoblast's current 3-Year ROIIC % of 14.06 is 101% above median its 10-year median of 7.01. Based on the distribution chart, Mesoblast ranks #494 out of 1324 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Mesoblast has a GF Score™ of 46/100, reflecting its overall financial health beyond just this single metric.
How does Mesoblast's 3-Year ROIIC % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Mesoblast ranks #494 out of 1324 companies for 3-Year ROIIC %. This puts Mesoblast in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Mesoblast and its competitors. Mesoblast's current 3-Year ROIIC % is 14.06, which is 101% above median its own 10-year median of 7.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mesoblast stock overvalued right now?
Mesoblast (ASX:MSB) has a current 3-Year ROIIC % of 14.06. The current 3-Year ROIIC % is 14.06, which is 101% above median its 10-year median of 7.01. Mesoblast's overall GF Score™ is 46/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Mesoblast (ASX:MSB), the current 3-Year ROIIC % is 14.06 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.
46GF Score
Get the complete analysis for ASX:MSB
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:MSB has been successfully added to your 
